Samuel H. A. Andersson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samuel H. A. Andersson has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Alexandru Schiopu
Department of Translational Medicine, Lund University , Malmö
1 shared publication - Amanda C. Foks
Division of BioTherapeutics, Leiden Academic Centre for Drug Research Leiden University Leiden the Netherlands
1 shared publication - Andrew Lichtman
Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
1 shared publication - Anthi Chalou
Department of Clinical Sciences, Malmö, Cardiovascular Research – Immune Regulation, Lund University, Malmö, Sweden
1 shared publication - Anton Gisterå
Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
1 shared publication Astrid Ericsson
Department of Clinical Sciences, Malmö, Cardiovascular Research – Immune Regulation, Lund University, Malmö, Sweden
1 shared publication
Latest Publications
- Open Access
- 7 October 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (10) , 1311-1328
Progenitor exhausted PD-1+ T cells are cellular targets of immune checkpoint inhibition in atherosclerosis
Immune checkpoint inhibitors (ICIs), targeting checkpoint receptors such as programmed cell death protein 1 (PD-1), are associated with increased risk of cardiovascular events, but the underlying mechanisms remain poorly understood. Here we show that PD-1+ T cells from murine atherosclerotic aortas mainly display a progenitor exhausted phenotype (PD-1intSlamf6+Tim3−), produce IFNγ in vivo, exhibit signs of recent proliferation and maintain polyfunctionality. PD-1 blockade induced marked changes in plaque immune phenotype, with increased PD-1high T cell accumulation, IFNγ production, formation of lymphocyte foci and neutrophil recruitment. Depletion of PD-1high T cells prior to PD-1 blockade did not impede T cell recruitment, suggesting a role for progenitor exhausted PD-1int T cells in ICI-driven T cell plaque accumulation. Human circulating PD-1+ T cells produced IFNγ and were associated with subclinical coronary atherosclerosis. Our studies highlight IFNγ-producing PD-1+ T cells as a potential key immune cell population mediating increased cardiovascular risk in patients with cancer receiving ICI.
- 7 October 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (10) , 1311-1328
Open AccessProgenitor exhausted PD-1+ T cells are cellular targets of immune checkpoint inhibition in atherosclerosis
Immune checkpoint inhibitors (ICIs), targeting checkpoint receptors such as programmed cell death protein 1 (PD-1), are associated with increased risk of cardiovascular events, but the underlying mechanisms remain poorly understood. Here we show that PD-1+ T cells from murine atherosclerotic aortas mainly display a progenitor exhausted phenotype (PD-1intSlamf6+Tim3−), produce IFNγ in vivo, exhibit signs of recent proliferation and maintain polyfunctionality. PD-1 blockade induced marked changes in plaque immune phenotype, with increased PD-1high T cell accumulation, IFNγ production, formation of lymphocyte foci and neutrophil recruitment. Depletion of PD-1high T cells prior to PD-1 blockade did not impede T cell recruitment, suggesting a role for progenitor exhausted PD-1int T cells in ICI-driven T cell plaque accumulation. Human circulating PD-1+ T cells produced IFNγ and were associated with subclinical coronary atherosclerosis. Our studies highlight IFNγ-producing PD-1+ T cells as a potential key immune cell population mediating increased cardiovascular risk in patients with cancer receiving ICI.